SESSION V: MYELOPROLIFERATIVE NEOPLASMS

Session Chair: Laura Michaelis and John Mascarenhas

Optimizing Selection of Available JAK Inhibitors in MF | Prithviraj Bose, MD | MD Anderson Cancer Center, Houston, Texas, USA

Clarifying Goals of Therapy in ET/PV | Laura C Michaelis, MD | Medical College of Wisconsin, Milwaukee, Wisconsin, USA

Novel Combination and Non-JAK Inhibitor Therapies on the Horizon | John O Mascarenhas, MD | Mount Sinai Medical Center, New York, New York, USA

Who, When, and How to Transplant Patients With MF | Roni Tamari, MD | Memorial Sloan Kettering Cancer Center, New York, New York, USA

Optimizing Outcomes of Accelerated and Blast Phase MPN | Naseema Gangat, MD | Mayo Clinic Rochester, Rochester, Minnesota, USA

Oral Abstract | MPN-384: A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients With Myeloid/Lymphoid Neoplasms With Fibroblast Growth Factor Receptor 1 (FGFR1) Gene Rearrangement | Jason R Gotlib, MD, MS | Stanford Cancer Institute, Stanford, California, USA